Bevacizumab used for the treatment of severe, refractory perilesional edema due to an arteriovenous malformation treated with stereotactic radiosurgery
Authors:
- Deric M. ParkDPDeric M. Park
- Jason P. SheehanJSJason P. Sheehan
- 1 May 2012
- journal article
- case report
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 116 (5) , 972-977
Abstract
The authors present a case of an arteriovenous malformation of the central sulcus treated with Gamma Knife surgery. The patient developed perilesional edema 9 months after treatment and experienced severe headache and hemiparesis. Her symptoms were refractory to corticosteroid therapy and pain management. She was subsequently treated with bevacizumab with striking improvement in her symptoms and results of neuroimaging studies. This is the first time that bevacizumab has been used to control severe refractory perilesional edema related to an intracranial arteriovenous malformation.Keywords
This publication has 26 references indexed in Scilit:
- Impact of bevacizumab chemotherapy on craniotomy wound healingJournal of Neurosurgery, 2011
- Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia‐associated epistaxisThe Laryngoscope, 2010
- A Systematic Review of the Literature on the Effects of Dexamethasone on the Brain From In Vivo Human-Based Studies: Implications for Physiological Brain Imaging of Patients With Intracranial TumorsNeurosurgery, 2010
- Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasiaAnnals of Hematology, 2010
- Repeat Gamma Knife Surgery for Incompletely Obliterated Cerebral Arteriovenous MalformationsNeurosurgery, 2010
- Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II studyBritish Journal of Cancer, 2009
- FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma MultiformeThe Oncologist, 2009
- Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant GliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasoneJournal of Neurosurgery, 1987